Chlamydia News and Research

Latest Chlamydia News and Research

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Abbott today announced financial results for the second quarter ended June 30, 2010.

21 Jul 2010

Cash rewards help combat STIs in rural Africa, study finds

Giving out cash can be an effective tool in combating sexually transmitted infections in rural Africa, according to a new study conducted jointly by researchers at the University of California, Berkeley, the Development Research Group at the World Bank and the Ifakara Health Institute in Tanzania.

20 Jul 2010

Emergent awarded $107M HHS BARDA contract to develop large-scale manufacturing of BioThrax

Emergent BioSolutions Inc. announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale manufacturing of BioThrax® (Anthrax Vaccine Adsorbed) in Building 55. Building 55 is the company's large-scale state-of-the-art vaccine manufacturing facility in Lansing, Michigan.

14 Jul 2010

Emergent BioSolutions hosts forum to raise global awareness of the importance of biopreparedness

Emergent BioSolutions Inc. is hosting "Bioterrorism Prevention, Preparedness and Response," a forum organized for members of the North Atlantic Treaty Organization Parliamentary Assembly to raise global awareness of the importance of biopreparedness.

13 Jul 2010

Inadequate funding for research, prevention will not help eradicate HIV in Quebec

On the XVIII International AIDS Conference's Eve (Vienna, Austria, July 18th to 23rd 2010), Mark Wainberg, PhD, co-director at Réseau Sida/Maladies infectieuses (FRSQ) and Dr. Réjean Thomas, president of clinique médicale l'Actuel denounce chronic underfunding in research and prevention related to HIV in Quebec and it's dramatic impact on the HIV epidemic and STI's. Researchers insist that the government double the amounts dedicated to these sectors.

13 Jul 2010

Erectile dysfunction drug user over 40 more likely to have sexually transmitted diseases

Physicians who prescribe erectile dysfunction drugs for their male patients should be sure to discuss the importance of safer sex practices, even with older patients: that is an important implication of a report in the July 6 issue of Annals of Internal Medicine. The analysis of insurance records of more than 1.4 million U.S. men over 40 found that those who used ED drugs were more likely to have sexually transmitted diseases than were non-users.

6 Jul 2010

Gen-Probe's APTIMA Trichomonas assay receives European CE mark

Gen-Probe Incorporated announced today that it has received a European CE mark for its APTIMA® assay for Trichomonas vaginalis, a common parasitic sexually transmitted disease.

1 Jul 2010

FDA grants Abbott 510(k) clearance to market molecular diagnostic test for detection of chlamydia, gonorrhea

Abbott announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market a new, sensitive molecular diagnostic test and instrument to simultaneously detect two of the nation's most prevalent sexually transmitted diseases (STDs), gonorrhea and chlamydia, including a new variant strain of chlamydia recently discovered in Sweden.

28 Jun 2010

Emergent BioSolutions completes sales, deliveries of BioThrax to allied international governments

Emergent BioSolutions Inc. announced today that it has completed separate international sales and deliveries of BioThrax® (Anthrax Vaccine Adsorbed) to governments of several allied nations. The company's international sales efforts have resulted in these sales of an undisclosed number of BioThrax doses for aggregate revenue of approximately $2.3 million in the second quarter.

24 Jun 2010

Small molecule ramps up interferon production in host cells, launching potent immune response

Many disease-causing microbes carry pumps that expel antibiotics, making the bugs hard to kill with standard drugs. Ironically, these same pumps could be the bugs' Achilles heel.

28 May 2010

Use of lubricants with anal sex associated with increased risk of rectal sexually transmitted infections

The risk of acquiring HIV through unprotected anal sex is at least 20 times greater than with unprotected vaginal sex and increases if other infections are already present in the rectal lining. Could the use of lubricants - at least certain kinds - be another risk factor among men and women who engage in receptive anal intercourse? Two studies presented today at the International Microbicides Conference in Pittsburgh, suggest the answer is yes.

27 May 2010

New test to detect HBV receives regulatory approval for use in the European Union

An inexpensive new test for the detection of Hepatitis B virus has been given regulatory approval for use in the European Union. The test, developed with support from the Wellcome Trust, delivers accurate results while-you-wait, enabling doctors to take immediate action on health decisions.

19 May 2010

Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review

Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.

17 May 2010

Emergent BioSolutions named Biotechnology Firm of the Year at TCM's Annual Tech Awards

Emergent BioSolutions Inc. announced today that it has been named Biotechnology Firm of the Year at the Tech Council of Maryland's Annual Tech Awards. This award acknowledges the company that best exemplifies the spirit of Maryland's biotechnology community as well as its presence and leadership within the state.

14 May 2010

Roche launches cobas(R) 4800 System in Canada for testing CT, NG and HPV

Roche Diagnostics Canada announced today the launch of a new Health Canada approved clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs. The cobas(R) 4800 System combines in vitro diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and human papillomavirus (HPV) testing with fully-automated sample preparation and real-time polymerase chain reaction (PCR) technology.

From Roche Sequencing and Life Science 7 May 2010

Emergent Biosolutions reports decreased revenue in 2010 first quarter

Emergent BioSolutions Inc. announced today its financial results for the first quarter ended March 31, 2010. For the first quarter 2010, total revenues were $46.8 million as compared to $64.5 million in 2009, and net income was $2.5 million, or $0.08 per share, as compared to $11.1 million, or $0.37 per share, in 2009.

6 May 2010

Gen-Probe reports total revenues of $135.4M for first-quarter 2010

Gen-Probe Incorporated today reported financial results for the first quarter of 2010, highlighted by $135.4 million of total revenues and earnings per share of $0.48 on both a non-GAAP and GAAP basis.

30 Apr 2010

Multicenter NIH trial finds combination antibiotics effective against Chlamydia-induced reactive arthritis

Combination antibiotics effectively treat Chlamydia-induced reactive arthritis - a major step toward management, and possibly cure, of this disease, a federal multicenter clinical trial led by the University of South Florida College of Medicine found.

29 Apr 2010

Combination of antibiotics can cure Chlamydia-induced ReA: Study

Researchers from University of South Florida College of Medicine found a combination of antibiotics to be an effective treatment for Chlamydia-induced reactive arthritis, a major step forward in the management, and possibly cure, of this disease. Results of this study are published in the May issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

29 Apr 2010

Genocea Biosciences, NMRC sign CRADA to develop vaccine against malaria

Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has entered into a Cooperative Research and Development Agreement with the Naval Medical Research Center. NMRC will collaborate with Genocea to identify antigens that will be used in the development of a vaccine candidate against Plasmodium falciparum for the prevention of malaria.

16 Apr 2010

Chlamydia News and Research

Latest Chlamydia News and Research

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Cash rewards help combat STIs in rural Africa, study finds

Emergent awarded $107M HHS BARDA contract to develop large-scale manufacturing of BioThrax

Emergent BioSolutions hosts forum to raise global awareness of the importance of biopreparedness

Inadequate funding for research, prevention will not help eradicate HIV in Quebec

Erectile dysfunction drug user over 40 more likely to have sexually transmitted diseases

Gen-Probe's APTIMA Trichomonas assay receives European CE mark

FDA grants Abbott 510(k) clearance to market molecular diagnostic test for detection of chlamydia, gonorrhea

Emergent BioSolutions completes sales, deliveries of BioThrax to allied international governments

Small molecule ramps up interferon production in host cells, launching potent immune response

Use of lubricants with anal sex associated with increased risk of rectal sexually transmitted infections

New test to detect HBV receives regulatory approval for use in the European Union

Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review

Emergent BioSolutions named Biotechnology Firm of the Year at TCM's Annual Tech Awards

Roche launches cobas(R) 4800 System in Canada for testing CT, NG and HPV

Emergent Biosolutions reports decreased revenue in 2010 first quarter

Gen-Probe reports total revenues of $135.4M for first-quarter 2010

Multicenter NIH trial finds combination antibiotics effective against Chlamydia-induced reactive arthritis

Combination of antibiotics can cure Chlamydia-induced ReA: Study

Genocea Biosciences, NMRC sign CRADA to develop vaccine against malaria

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Chlamydia News and Research

Latest Chlamydia News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in